Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Beijing Hospital |
---|---|
Information provided by: | Beijing Hospital |
ClinicalTrials.gov Identifier: | NCT00752947 |
The purpose of this study is to determine whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration factors.
Condition | Intervention | Phase |
---|---|---|
Community-Acquired Pneumonia |
Drug: moxifloxacin Drug: levofloxacin Drug: metronidazole |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors |
Estimated Enrollment: | 186 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: moxifloxacin
Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
|
B: Active Comparator |
Drug: levofloxacin
Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
Drug: metronidazole
metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
|
186 patients in 4 centers will be enrolled in this study. Patients accord with the criteria of CAP with aspiration factors will be enrolled and randomized to one of the following groups. The treatment duration will range from 2 to 4 weeks.
Study Group: Intravenous treatment with moxifloxacin 400mg i.v. OD. Based on investigator's decision, a switch can be made to moxifloxacin 400 mg OD, orally (Moxifloxacin injection will be used no more than 3 weeks consecutively) .
Control Group: Intravenous treatment with levofloxacin 400mg i.v. OD plus metronidazole 0.5g i.v. bid. Based on investigator's decision, a switch can be made to levofloxacin 400mg OD plus metronidazole 0.2g tid, orally.
Treatment should be continued until complete resolution of the radiological, clinical and laboratory alterations or until no further regression can be observed. Clinical, bacteriological, laboratory and radiological examinations will be performed pre-treatment. Swallowing/coughing reflection test will be used for aspiration factor diagnosis. Risk factors (Decreased level of consciousness, dysphagia, gastroesophageal reflux, neurologic disease, mechanical and device-related (e.g. nasogastric feeding tube) impairment of upper aerodigestive tract, vomiting, bronchial obstruction due to neoplasm or foreign body, bronchiectasis, pulmonary infarction, etc) will be evaluated before the treatment. Clinical and laboratory examinations such as blood routine(including Hb, differential blood count, etc), urine routine, biochemistry examination (including serum bilirubin, hepatic/renal function parameters, etc), coagulation examination will be repeated selectively. Radiological examination (e.g. chest x-ray) will be repeated at each visit for clinical monitoring after one week treatment. At the test-of-cure visit (7-14 days after the end of therapy) comprehensive clinical, bacteriological and laboratory examinations will be performed.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
HIV-positive patients may be included. HIV testing is not required for this study protocol.
Contact: Tieying Sun | 86-10-13701034257 | suntieying3@hotmail.com |
China | |
Xiuhong Nie | Not yet recruiting |
Beijing, China | |
Tieying Sun | Recruiting |
Beijing, China |
Principal Investigator: | Tieying Sun | Beijing Hospital |
Responsible Party: | Beijing Hospital ( Prof. Sun Tieying ) |
Study ID Numbers: | MOHBJH-STY-1 |
Study First Received: | September 15, 2008 |
Last Updated: | March 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00752947 History of Changes |
Health Authority: | China: State Food and Drug Administration |
Anti-Bacterial Agents Metronidazole Radiation-Sensitizing Agents Respiratory Tract Infections Respiratory Tract Diseases |
Moxifloxacin Lung Diseases Ofloxacin Anti-Infective Agents, Urinary Pneumonia |
Metronidazole Anti-Infective Agents Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Ofloxacin Physiological Effects of Drugs Anti-Infective Agents, Urinary Enzyme Inhibitors Renal Agents Pharmacologic Actions |
Anti-Bacterial Agents Antiparasitic Agents Respiratory Tract Diseases Respiratory Tract Infections Radiation-Sensitizing Agents Moxifloxacin Lung Diseases Therapeutic Uses Nucleic Acid Synthesis Inhibitors Pneumonia |